该词条未找到_海词词典

您要查找的是不是：

The name is soluble f-m-s-like tyrosine kinase one? 这种蛋白质叫做可溶解fms样酪氨酸激酶一，
OBJECTIVE:To discuss the progress and the clinical application evaluation of protein tyrosine kinase(PTK) inhibitors. 目的:探讨酪氨酸激酶抑制剂的进展与临床应用评价。
Objective To approach the mechanism of action of anticancer and the investigation progress of protein tyrosine kinase (PTK). 摘要目的探讨蛋白酪氨酸激酶抑制剂抗肿瘤作用机理及其研究进展。
Objective To approach the mechanism of action of anticancer and the investigation progress of protein tyrosine kinase(PTK). 目的探讨蛋白酪氨酸激酶抑制剂抗肿瘤作用机理及其研究进展。
Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer? PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用?
Receptor tyrosine kinase (RTK), a membrane receptor superfamily with intrinsic protein tyrosine kinase activity, has many members and complicated signal transduction pathways. 摘要受体酪氨酸激酶是一个具有内在酪氨酸蛋白激酶活性的膜受体超家族，成员众多，信号转导通路复杂多样。
The inhibitor of VEGF receptor tyrosine kinase was introduced in detail. 详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。
Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor. 苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
The ABL gene encodes a tyrosine kinase whose activity is tightly regulated. ABL基因编码一种活性受到严格调控的酪氨酸激酶。
DDR2 is a newly identified receptor protein tyrosine kinase, which is composed of three parts: DR region on the N terminus, a long justatransmembrane region (JM) between DR region and transmembrane region, and intracellular region in cytoplasma. DDR2是一类新发现的受体型蛋白酪氨酸激酶，其分子结构由三部分组成：一是N端的DR区，二是在DR与跨膜区之间的很长的邻跨膜区(justatransmembrane region，JM)，三是在胞浆内的胞内区。
ABSTRACT STI571 is one of the target drugs to Bcr/Abl oncoprotein.It is a special inhibitor to the activation of protein tyrosine kinase by interrupting phosphorylation of substrate. 摘要 STI571 是一种针对Bcr/Abl基因表达产物的靶向治疗药物，可以阻止底物的酪氨酸残基磷酸化，发挥特异性酪氨酸蛋白激酶活性抑制作用，临床研究结果证明对慢性粒细胞白血病的疗效显著优于干扰素及其它化疗药物。
FGFR3, a member of polypeptide growth factor family, is a tyrosine kinase receptor. FGFR3是这一多肽类生长因子的家族成员之一，它是一种酪氨酸激酶受体。
The progress in tyrosine kinase inhibitor has been reviewed, including the chemical structures and the pharmacophore models. 本文综述了近年来酪氨酸激酶抑制剂的研究进展，包括抑制剂的结构和与激酶作用的药效团模型。
Isoflavone. Inhibitor of EGFR tyrosine kinase, blocking phosphatidylinositol turnover. 异黄酮类。抑制EGFR酪氨酸激酶。阻断磷脂酰肌糖的翻转。
STI571 could induce leukemia cells of ANLL into terminal differentiation by inhibiting c-kit tyrosine kinase. STI571对急性非淋巴细胞白血病原代细胞有诱导向同系终末分化的作用,对c-kit酪氨酸激酶有明显的抑制作用,且与药物浓度相关。
Objective:To explore the mutation of receptor tyrosine kinase ( RET ) gene in sporadic medullary thyroid carcinoma. 目的:研究散发型甲状腺髓样癌酪氨酸激酶受体基因(RET)的突变情况。
The structures and functions of EGFR as well as current status of EGFR tyrosine kinase inhibitors are reviewed. 综述了EGFR的结构和作用以及近年来EGFR酪氨酸激酶抑制剂的研究进展。
Trastuzumab is a monoclonal antibody that directly targets part of the HER2 tyrosine kinase receptor. 曲妥单抗是一种直接针对HER2酪氨酸激酶受体的单抗。
We got 10 phage clones which could bind with wild-type and mutant Bcr/Abl tyrosine kinase domain. （2）用菌体呈现随机7肽库对构建表达的激酶域蛋白进行了生物淘筛，得到了10个与两种类型激酶域均能结合的共用型噬菌体克隆。
Gefitinib, the first EGFR tyrosine kinase inhibitor put into clinical trial, was put into market in Japan in 2002. 吉非替尼是EGFR酪氨酸激酶抑制剂中最早进入临床试验的口服药物，2002年首次于日本上市。